Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

4

US Approved Rx

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Human immunodeficiency virus type 1 protease

4

Leishmania amazonensis

4

UDP-glucuronosyltransferase 1-1

4

Human immunodeficiency virus type 1 integrase

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1996

4

2012

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

HIV infection

4

HIV-1 infection

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

5

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

5

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Merck

4

Japan Tobacco

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

5

PUBCHEM

5

CAS

4

DAILYMED

4

DRUG BANK

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIVIRALS FOR SYSTEMIC USE

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DIRECT ACTING ANTIVIRALS

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Protease inhibitors

2

Antivirals for treatment of HIV infections, combinations

1

Other antivirals

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ELVITEGRAVIR

4GDQ854U53

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 2012

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Human immunodeficiency virus type 1 integrase

Conditions:

HIV-1 infection

Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor used in combination with cobicistat, emtricitabine and tenofovir alafenamid (GENVOYA®) for the treatment of HIV-1 infection in antiretroviral treatment-...

experienced adults. Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome and thereby blocks the formation of the HIV-1 provirus and resulting propagation of the viral infection.

INDINAVIR ANHYDROUS

9MG78X43ZT

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1996

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

UDP-glucuronosyltransferase 1-1

Human immunodeficiency virus type 1 protease

Leishmania amazonensis

Conditions:

Indinavir is an antiretroviral drug for the treatment of HIV infection. Indinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is ...

an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

INDINAVIR SULFATE

771H53976Q

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1996

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

UDP-glucuronosyltransferase 1-1

Human immunodeficiency virus type 1 protease

Leishmania amazonensis

Conditions:

Indinavir is an antiretroviral drug for the treatment of HIV infection. Indinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is ...

an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

INDINAVIR

5W6YA9PKKH

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1996

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

UDP-glucuronosyltransferase 1-1

Human immunodeficiency virus type 1 protease

Leishmania amazonensis

Conditions:

Indinavir is an antiretroviral drug for the treatment of HIV infection. Indinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is ...

an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

INDINAVIR SULFATE ETHANOLATE

34OB95C8AE

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1996

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

UDP-glucuronosyltransferase 1-1

Human immunodeficiency virus type 1 protease

Leishmania amazonensis

Conditions:

Indinavir is an antiretroviral drug for the treatment of HIV infection. Indinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is ...

an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1